Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis

被引:138
作者
Cooper, N [1 ]
Rao, K [1 ]
Gilmour, K [1 ]
Hadad, L [1 ]
Adams, S [1 ]
Cale, C [1 ]
Davies, G [1 ]
Webb, D [1 ]
Veys, P [1 ]
Amrolia, P [1 ]
机构
[1] Great Ormond St Hosp Sick Children, London WC1N 3JH, England
关键词
D O I
10.1182/blood-2005-05-1819
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Allogeneic stem cell transplantation (SCT) is curative for hemophagocytic lympho-histiocytosis (HLH). However, patients frequently have significant morbidity before transplantation and there is high transplant-related mortality (TRM). Because first-degree HLH is caused by immune dysregulation, a reduced-intensity conditioned (RIC) regimen might be sufficient for cure while decreasing the TRM. Twelve patients with HLH underwent RIC SCT from a matched family/unrelated or haploidentical donor. Eleven were conditioned with fludarabine/melphalan with additional busulphan for haploidentical grafts. One received fludarabine and 2-Gy total body irradiation (TBI). All patients showed engraftment at a median of 14 days. Nine of 12 (75%) are alive and in complete remission (CR) a median of 30 months (range, 9-73 months) after SCT. Two patients died from pneumonitis and one from hepatic rupture. Four patients developed acute graft-versus-host disease (GVHD) and 3 have chronic GVHD. Three of 9 survivors have mixed chimerism but remain free of disease. In summary, RIC compares favorably to conventional SCT with long-term disease control in surviving patients despite a significant incidence of mixed chimerism.
引用
收藏
页码:1233 / 1236
页数:4
相关论文
共 18 条
  • [1] Outcome for children after failed transplant for primary haemophagocytic lymphohistiocytosis
    Ardeshna, KM
    Hollifield, J
    Chessells, JM
    Veys, P
    Webb, DKH
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) : 949 - 952
  • [2] Arico M, 1996, LEUKEMIA, V10, P197
  • [3] Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene
    Arico, M
    Imashuku, S
    Clementi, R
    Hibi, S
    Teramura, T
    Danesino, C
    Haber, DA
    Nichols, KE
    [J]. BLOOD, 2001, 97 (04) : 1131 - 1133
  • [4] BLANCHE S, 1991, BLOOD, V78, P51
  • [5] Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis
    Egeler, RM
    Shapiro, R
    Loechelt, B
    Filipovich, A
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1996, 18 (04) : 340 - 345
  • [6] NATURAL-KILLER CELL-FUNCTION AND INTERFERON-PRODUCTION IN FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
    EIFE, R
    JANKA, GE
    BELOHRADSKY, BH
    HOLTMANN, H
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1989, 6 (03) : 265 - 272
  • [7] Sequence analysis of the granulysin and granzyme B genes in familial hemophagocytic lymphohistiocytosis
    Ericson, KG
    Fadeel, B
    Andersson, M
    Gudmundsson, GH
    Gürgey, A
    Yalman, N
    Janka, G
    Nordenskjöld, M
    Henter, JI
    [J]. HUMAN GENETICS, 2003, 112 (01) : 98 - 99
  • [8] Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis
    Ericson, KG
    Fadeel, B
    Nilsson-Ardnor, S
    Söderhäll, C
    Samuelsson, A
    Janka, G
    Schneider, M
    Gürgey, A
    Yalman, N
    Révész, T
    Egeler, RM
    Jahnukainen, K
    Storm-Mathiesen, I
    Haraldsson, A
    Poole, J
    de Saint Basile, G
    Nordenskjöld, M
    Henter, JI
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (03) : 590 - 597
  • [9] Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3)
    Feldmann, J
    Callebaut, I
    Raposo, G
    Certain, S
    Bacq, D
    Dumont, C
    Lambert, N
    Ouachée-Chardin, M
    Chedeville, G
    Tamary, H
    Minard-Colin, V
    Vilmer, E
    Blanche, S
    Le Deist, F
    Fischer, A
    Saint Basile, GD
    [J]. CELL, 2003, 115 (04) : 461 - 473
  • [10] Biology and treatment of familial hemophagocytic lymphohistiocytosis: Importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis
    Henter, JI
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 38 (05): : 305 - 309